Simvastatin / sitagliptin Side Effects
Very common (10% or more): Eczema
Uncommon (0.1% to 1%): Rash
Very common (10% or more): Urinary tract infection
Very common (10% or more):Elevation of creatinine kinase (CK)
Frequency not reported: Elevated alkaline phosphatase and gamma-glutamyl transpeptidase
Postmarketing reports: Anemia
Elevation of CK levels of 3 or more times the normal value has been reported. This was attributable to the noncardiac fraction of CK.
Sitagliptin: Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database. Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor. In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain. In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation. A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor. Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).[Ref]
Very common (10% or more): Myalgia
Uncommon (0.1% to 1%): Asthenia
Rare (less than 0.1%): Myopathy, rhabdomyolysis
Postmarketing reports: Immune-mediated necrotizing myopathy
Common (1% to 10%): Abdominal pain, constipation, nausea, flatulence
Uncommon (0.1% to 1%): Acid regurgitation, diarrhea, dyspepsia, pancreatitis
Postmarketing reports: Pancreatitis, acute pancreatitis, including fatal and non-fatal hemorrhagic and necrotizing pancreatitis, constipation, vomiting
Common (1% to 10%): Hypoglycemia
Common (1% to 10%): Headache
Common (1% to 10%): Upper respiratory infection, bronchitis, sinusitis
Common (1% to 10%): Upper respiratory tract infections, nasopharyngitis
Postmarketing reports: Interstitial lung disease[Ref]
Uncommon (0.1% to 1%): Elevated transaminases
Postmarketing reports: Hepatitis/jaundice, fatal and non-fatal hepatic failure, hepatic enzymes elevation
Postmarketing reports: Anaphylaxis, angioedema, lupus erythematous-like syndrome, polymyalgia rheumatic, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticarial, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme (including Stevens-Johnson syndrome).
Postmarketing reports: Anaphylaxis, angioedema, rash, urticarial, cutaneous vasculitis, exfoliative skin conditions including Stevens-Johnson syndrome[Ref]
Postmarketing reports: Worsening of renal function, including acute renal failure (sometimes requiring dialysis)[Ref]
Postmarketing reports: Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion)
Postmarketing reports: Depression
Cognitive impairment is reversible up on statin discontinuation.
1. "Product Information. Juvisync (simvastatin-sitaGLIPtin)." Merck & Company Inc, Whitehouse Station, NJ.
2. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf." ([2015, Aug 28]):
More about simvastatin / sitagliptin
- During Pregnancy
- Dosage Information
- Drug Interactions
- Drug class: antidiabetic combinations
- FDA Alerts (6)
- Other brands
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.